Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading Canadian specialty pharmaceutical company, and S.I.F.I- Società Industria Farmaceutica Italiana S.p.A. (“SIFI”), a prominent Italian Eye Care company, today announced that...

> read on

MINI WELL Ready IOL, a premium solution for Extended Range of Vision February 10th from 1-2 PM in Room: N201B Speakers: Dr. Victor Caparas Dr. Christopher Khng Dr. Santaro Noguchi Prof. Gerd Auffarth   New Advancements in Intra-Ocular Lens...

> read on

SIFI announces an important development in the innovative SoundMedsTM service, dedicated to patients with difficulty in reading product information leaflets. The audio service, which allows users to listen to the information leaflet associated with SIFI...

> read on

SIFI SYMPOSIUM during SOI Congress Between therapeutic effectiveness, quality of vision and life: New goals in patient diabetic macular edema management Centro Congressi Rome Cavalieri Friday December 1st 2017 -  2.30/4.00 PM Sala Belle Arti,...

> read on

One step closer to the European registration of a safe and effective drug for the treatment of Acanthamoeba Keratitis. SIFI is pleased to announce that AIFA (Italian Medicines Agency) has issued the official authorization to start Phase III clinical...

> read on